Introduction
Spinocerebellar ataxias (SCAs) are adult-onset neurodegenerative disorders with autosomal dominant inheritance. Several SCAs are caused by CAG repeat expansions (CAGexp) within coding regions of unrelated genes, being translated into neurotoxic polyglutamine-containing proteins [1] .
In SCA type 3/Machado-Joseph disease (SCA3/ MJD), CAGexp length determines~50% of age at onset (AO) variability [2] [3] [4] [5] . Although the average (range) CAGexp length in European and North American patients with SCA3/MJD was found to be 68.0 (54-77) [3, 6, 7] , these values are skewed towards longer repeats (average, 75.1; range, 65-91) in Brazilian carriers [6, 8] . A younger AO was consistently observed in Brazilian patients, when compared with European and North American patients [2, 3, 6, [8] [9] [10] [11] .
Prediction of AO might impact genetic counselling and recruitment of pre-ataxic individuals for future clinical trials. To address this issue, maximum likelihood estimation of AO of first symptoms was previously used in SCA3/MJD [12] , whereas others employed parametric survival models to estimate the probability of onset at a given age in Huntington's disease (e.g. [13] ) and in Cuban SCA type 2 [14] , European SCA type 1, SCA type 2, SCA3/MJD and SCA6 carriers [7] . These models were assumed to be applicable to independent patient cohorts. Recent evidence, however, suggests that additional CAGexpindependent factors might influence AO [4] , arguing against a single AO prediction model and suggesting that the population background should be considered.
Here, we compared known AO of gait ataxia (AOga) in SCA3/MJD with predictions from the published European model [7] , using independent cohorts from distinct geographical origins, i.e. South Brazil, Taiwan and the Portuguese Azorean Islands. We then developed and validated population-specific models for South Brazilian [Brazilian formula (BF)] and Taiwanese [Taiwanese formula (TF)] carriers.
Methods
A workflow illustrating the cohorts and analysis rationale used in this study is shown in File S1. Subjects with SCA3/MJD (n = 739) were stratified according to geographical origin. AOga was considered to be the age at the first walking disturbances, as reported by carriers and/or relatives (File S2 for details).
Study populations
South Brazilian cohort 1 A total of 100 symptomatic and 50 asymptomatic carriers were recruited from the Rio Grande do Sul SCA3/MJD population [8] . Their data were used to test the model built with data from European patients, referred here as to 'European formula' (EF) for AOga determination [7] (validation cohort for EF) and to generate BF (discovery cohort for BF).
South Brazilian cohort 2
An additional 107 patients from the South Brazilian SCA3/MJD population [8] were enrolled in a validation cohort to address predictions of BF, EF and TF.
Taiwanese cohort 3 A total of 40 asymptomatic and 227 symptomatic Taiwanese individuals, randomly assigned from an original cohort of 347 symptomatic subjects, were used to test EF (validation cohort for EF) and to generate TF (discovery cohort for TF).
Taiwanese cohort 4
The remaining 120 symptomatic Taiwanese individuals composed a validation cohort to address predictions of BF, EF and TF.
Portuguese Azorean cohort 5 A total of 95 symptomatic individuals from the Portuguese Azorean Islands [4] were used to test BF, EF and TF. SCA3/MJD in South Brazil is virtually entirely traced back to Azoreans who settled in this region between 1750 and 1770 [15] . Due to this genetic closeness, cohort 5 was chosen to validate prediction differences between BF and EF.
Clinical and molecular diagnosis
Individuals were genotyped at their local institutions where this study was conducted. Length of CAG repeats was determined by polymerase chain reaction using fluorescent primers for the ATXN3 CAG repeat region and capillary electrophoresis.
Ethical aspects
This study was approved by the Ethics Committees of Hospital de Cl ınicas de Porto Alegre (14-0204), University of Azores (2/2016) and Shuang Ho Hospital, Taiwan. Confidentiality was guaranteed to all study participants, who gave written informed consent to participate in the study. Results from Brazilian (n = 50) and Taiwanese (n = 40) asymptomatic individuals were dealt with in a pseudonymized manner under an arrangement that ensured that results were not disclosed to anyone except the principal investigators in Brazil (L.B.J.) and Taiwan (B.W.-S.), respectively.
Statistical analysis
Prediction of median AOga for a given CAGexp length was calculated for all individuals from South Brazilian cohort 1, Taiwanese cohort 3 and Portuguese Azorean cohort 5, using EF for AOga determination [7] . Critical ranges (5th and 95th percentiles) were obtained for predicted AOga (File S3). Scatter plots were used to compare differences between observed and predicted AOga in symptomatic individuals from all cohorts or between the age at the last asymptomatic neurological evaluation and the predicted AOga for asymptomatic individuals. Differences between observed and predicted values, expressed as mean prediction errors, were assessed by paired t-tests. Positive mean prediction errors indicated underestimations (observed AOga À predicted AOga > 0 years). Inaccurate AOga predictions for asymptomatic carriers were only detected when the predicted AO was earlier than the actual age of the individual at the time of her/his last clinical evaluation.
New prediction models were developed using data from the South Brazilian cohort 1 (BF) and Taiwanese cohort 3 (TF). For each cohort, data from symptomatic and asymptomatic carriers were fitted to four parametric survival models (log-normal, Gaussian, exponential and Weibull). The best-fitting models were chosen through residual analysis, Akaike information criterion and visual comparison with KaplanMeier curves (File S4). As data from both cohorts were better explained by a Gaussian parametric survival model, we adapted EF [7] to accommodate a Gaussian distribution (Files S5, S6 and S7).
Both BF and TF were fitted in the statistical software R [16] , version 3.2.2, using the survreg function from the survival package. The print.psm function from the rms package was used to calculate R² [17] . Results were considered statistically significant when P < 0.05.
Results
Age at onset and CAG length of the expanded allele differences among distinct spinocerebellar ataxia type 3/Machado-Joseph disease populations South Brazilian cohorts had mean AO of first symptoms, AOga and CAGexp values very similar to those reported previously for this population [8] . Mean CAGexp was statistically different among Portuguese Azorean (smaller mean CAGexp), Taiwanese (intermediate) and South Brazilian carriers (larger mean CAGexp) (two-tailed ANOVA with Tukey's post hoc test, F 2,736 = 69.51, P < 0.05) ( Table 1) . However, mean AOga was only significantly different between Taiwanese and South Brazilian patients (F 2,646 = 5.08, P < 0.05).
Accuracy of the European prediction model (European formula)
The EF underestimated known AOga of South Brazilian (Fig. 1a) and Taiwanese (Fig. 1b) patients. Mean prediction errors ranged from almost 6 years (Taiwanese group) to more than a decade (South Brazilian group) (File S8). EF predictions were more accurate for Portuguese Azorean patients ( Fig. 1c and File S8).
The EF also underestimated the predicted AOga of South Brazilian and Taiwanese asymptomatic carriers (File S9). For 33/50 (66.0%) South Brazilian and 21/40 (52.5%) Taiwanese pre-clinical carriers, EF predicted younger AOga than the age of the individuals at the last asymptomatic neurological evaluation. Underestimations had a median of 6.93 (25th percentile, 5.31; 75th percentile, 13.71) and 6.12 (25th percentile, 3.44; 75th percentile, 13.42) years for South Brazilian and Taiwanese asymptomatic carriers, respectively.
Development and validation of population-specific models for age at onset of gait ataxia prediction Based on parameters estimated from the South Brazilian cohort 1 and Taiwanese cohort 3 (Methods and File S7), new models BF and TF were respectively generated and used to estimate AOga in carriers within a wide range of CAGexp lengths (Fig. 2a and  b , Files S5 and S6). CAGexp explained, on average, 58.9% and 50.0% of AOga variance in the South Brazilian cohort 1 and Taiwanese cohort 3, respectively. Inclusion of CAG length at the non-expanded ATXN3 allele was not significant (BF, P = 0.352; TF, P = 0.907).
The BF and TF were then validated in the South Brazilian cohort 2, Taiwanese cohort 4 and Portuguese Azorean cohort 5. BF was accurate for South Brazilian individuals (Fig. 3a) , but yielded large overestimations in Taiwanese (Fig. 3b) and Portuguese Azorean (Fig. 3c) patients (File S8) . A similar population specificity was observed for TF, which was more accurate for Taiwanese carriers (Fig. 3e) when compared with predictions for South Brazilian (Fig. 3d) and Portuguese Azorean (Fig. 3f ) individuals (Files S8 and S9). Excel files were made available to estimate AOga according to CAGexp for European (EF), Brazilian (BF) and Taiwanese (TF) SCA3/MJD carriers (Files S3, S5 and S6, respectively).
Discussion
The EF largely underestimated AOga in South Brazilian and Taiwanese SCA3/MJD carriers, even in subjects with CAGexp tracts in the range seen in European carriers. We then developed Brazilian and Taiwanese prediction models and validated them exclusively in a population-specific manner. These data suggest that (i) different AOga prediction formulas should be used for distinct ethnic groups and (ii) CAGexp at ATXN3 has a differential contribution to AOga in distinct populations, possibly due to population-specific modifying factors.
Differences in AO and CAGexp between European and South Brazilian SCA3/MJD carriers have been acknowledged for a long time [8] . Although South Brazilian SCA3/MJD individuals tend to have longer CAGexp tracts than Europeans [2, 3, 5, 6, [8] [9] [10] [11] , we expected that EF should be more accurate, at least for individuals with expansions within the European range. However, this was not the case (Fig. 1a and b , and Files S8, S9 and S10). For instance, EF predicted AOga at 39.6 years for individuals with 68 CAG repeats, whereas BF and TF predicted much later AOga, i.e. 57.5 and 47.0 years, respectively (Files S3, S5 and S6). Populational specificity for the CAGexp-AO relationship was also suggested by the fact that the Gaussian model yielded the best fit for South Brazilian and Taiwanese cohorts, instead of the log-normal model used for EF [7] . We speculate that, if the ATXN3 CAGexp range observed in South Brazilians occurred among Europeans, the effect on AOga would have disastrous consequences, producing very early-onset cases.
As BF largely overestimated AOga for Portuguese Azoreans, perhaps the European pattern of AOga dependency on CAGexp might have suffered a bottleneck/founder effect when Portuguese Azoreans settled in South Brazil. These settlers might have brought longer CAGexp tracts than the median expansion range from the original European population and simultaneously might have encoded protective factors, maybe in cis with CAGexp, that resulted in delayed disease onset and partially counterbalance the anticipatory effect of longer CAGexp in South Brazil. Conversely, there could be protective factors in the general population background, either genetic or environmental.
Although it is difficult to foresee the accuracy of predictions using EF, BF and TF in cohorts from other geographical origins, we anticipate that these models will require further local adjustments of parameters.
In conclusion, EF, BF and TF were validated for Portuguese Azorean, South Brazilian and Taiwanese SCA3/MJD carriers, respectively. We generated open access files that help to predict AOga according to a given CAGexp length, both at birth and at any given age for evaluation, for European, South Brazilian and Taiwanese carriers (Files S3, S5 and S6, respectively). If regional differences in AOga determination are confirmed in additional SCA3/MJD cohorts, this finding could have a deep impact not only on genetic counselling and on recruitment strategies of asymptomatic individuals for clinical trials, but also on the search for modifier factors that delay disease onset. 
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